Prophase will now move to accelerated commercialization of BE-Smart TM with expected clinical launch in the next 2-3 quarters.

Detailed price information for Prophase Labs Inc (PRPH-Q) from The Globe and Mail including charting and trades.

UNIONDALE, NY, June 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the ...

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate ...

UNIONDALE, NY - ProPhase Labs Inc. (NASDAQ:PRPH) has received a 180-day extension from Nasdaq to regain compliance with the exchange's minimum $1.00 bid price requirement, the biotech company ...

UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today ...

ProPhase Labs received a 180-day extension from Nasdaq to meet its $1.00 bid price compliance requirement.

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating ...

ProPhase Labs , Inc. (NASDAQ: PRPH) announced the appointment of Carolina Abenante, Esq. as an independent director to its Board of Directors, effective Friday. According to a statement based on a ...

About ProPhase Labs Inc. ProPhase Labs Inc. (Nasdaq: PRPH) ("ProPhase") is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold ...